Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Review, H1 2013

Global Markets Direct
May 27, 2013
23 Pages - SKU: GMD5053917


Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH). Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Aneurysmal Subarachnoid Hemorrhage (SAH).
  • A review of the Aneurysmal Subarachnoid Hemorrhage (SAH) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Aneurysmal Subarachnoid Hemorrhage (SAH).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Aneurysmal Subarachnoid Hemorrhage (SAH) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Additional Information


Report Excerpt

Appendix

Methodology


Global Markets Direct dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise.

Global Markets Direct adheres to the Codes of Practice of the Market Research Society and the

All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

More Drug Discovery reports by Global Markets Direct

Chronic Pain - Pipeline Review, H2 2014 by Global Markets Direct
Chronic Pain - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2014’, provides an overview of the Chronic Pain’s therapeutic pipeline.This ...
Malaria - Pipeline Review, H2 2014 by Global Markets Direct
Malaria - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Malaria - Pipeline Review, H2 2014’, provides an overview of the Malaria’s therapeutic pipeline.This report provides comprehensive ...
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014 by Global Markets Direct
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 ...
Primary Dysmenorrhea - Pipeline Review, H2 2014 by Global Markets Direct
Primary Dysmenorrhea - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Primary Dysmenorrhea - Pipeline Review, H2 2014’, provides an overview of the Primary Dysmenorrhea’s therapeutic pipeline.This ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!